When a Toronto psychiatrist recommended abruptly tapering off 19 years of daily Klonopin use, a patient agreed, expecting three weeks of mild discomfort. What followed was months of severe, disabling symptoms that doctors struggled to recognize or treat.
According to the source account, withdrawal symptoms began within two days of reducing the dose. Tingling in the hands progressed to numbness spreading across the limbs, accompanied by tinnitus at “shocking levels,” severe insomnia, and excessive sweating that caused a 10-pound weight loss. The patient developed paresthesia, stabbing neck pain, depersonalization, and heightened sensitivity to sensory input. Fasciculation—involuntary muscle twitching—appeared in the biceps. Morning vomiting lasted up to 20 minutes. Most distressing was a sensation described as “being electrocuted for hours on end,” distinct from typical SSRI withdrawal symptoms, combined with compulsive finger movements and akathisia.
These symptoms led to multiple misdiagnoses: cervical radiculopathy and arthritis. The patient’s general practitioner remained baffled, and anxiety about the unexplained condition intensified existing mental health struggles. The situation deteriorated to active suicidality with planning.
Relief came through an online support community where members recommended Dr. Heather Ashton’s 1999 manual “Benzodiazepines: How They Work and How to Withdraw.” The Ashton Manual detailed every symptom the patient was experiencing and described benzodiazepine withdrawal syndrome (BWS).
Benzodiazepines—including alprazolam (Xanax), lorazepam (Ativan), diazepam (Valium), and clonazepam (Klonopin)—are among America’s most widely prescribed medications. Data from 2015-2016 showed an estimated 30.6 million American adults had taken benzodiazepines in the previous 12 months, with 25.3 million using them as prescribed.
According to the Ashton Manual, 10 to 15 percent of benzodiazepine users may experience protracted withdrawal. Other researchers, including Sean Hood from the University of Western Australia’s School of Psychiatry, estimate the figure could reach 40 percent. Yet medical schools typically dedicate only a few hours to studying benzodiazepines.
In 2020, the FDA added a boxed warning to benzodiazepines noting that “clinically significant physical dependence” and “life-threatening” withdrawal reactions are possible. However, Dr. Alexis Ritvo, an addiction psychiatrist and medical director of the Alliance for Benzodiazepine Best Practices, notes that “there is no formal way prescribers are required to be educated about” these warnings.
Professor Malcolm Lader from King’s College London began warning about benzodiazepine risks in the 1970s. In 1981, he described an “epidemic in the making,” and in 1999 stated it was “more difficult to withdraw people from benzodiazepines than it is from heroin.”
Key facts
- Benzodiazepines are prescribed to an estimated 30.6 million American adults annually, with 25.3 million using them as prescribed.
- Withdrawal symptoms can include paresthesia, tinnitus, severe insomnia, hyperhidrosis, depersonalization, fasciculation, and sensations of electrical shocks.
- 10 to 15 percent of benzodiazepine users may experience protracted withdrawal, though some researchers estimate up to 40 percent.
- Medical schools typically dedicate only a few hours to studying benzodiazepines despite their widespread use.
- The FDA added a boxed warning in 2020 noting benzodiazepines can cause clinically significant physical dependence and life-threatening withdrawal reactions.